Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
- 1 October 1996
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 78 (7), 747-750
- https://doi.org/10.1016/s0002-9149(96)00414-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pharmacokinetics of RheothRx Injection in Healthy Male VolunteersJournal of Pharmaceutical Sciences, 1997
- Incidence and Importance of Thrombolysis in Myocardial Infarction Grade 3 Flow After Primary Percutaneous Transluminal Coronary Angioplasty for Acute Myocardial InfarctionThe American Journal of Cardiology, 1996
- Beneficial Effects of RheothRx Injection in Patients Receiving Thrombolytic Therapy for Acute Myocardial InfarctionCirculation, 1996
- Factors influencing myocardial salvage with primary angioplastyJournal of Nuclear Cardiology, 1995
- Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function.Circulation, 1994
- Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: Implications for the design of randomized trials of acute interventionJournal of the American College of Cardiology, 1994
- Haemorheological effects of a nonionic copolymer surfactant (Poloxamer 188)Clinical Hemorheology and Microcirculation, 1992
- The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinaseFibrinolysis, 1990
- Increased Whole Blood Viscosity during Coronary Artery Bypass SurgeryThrombosis and Haemostasis, 1990